Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation

GBI Research has released the pharma report: "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation", which identifies and assesses first-in-class innovation in the psoriasis development pipeline.

Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including safety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful.

Full Report Details at
- http://www.fastmr.com/prod/851396_frontier_pharma_psoriasis_identifying_and.aspx?afid=301

This allows for pipeline programs that offer a more refined approach to immunomodulation and ease of drug application to gain market share upon entry. In a pipeline of over 200 programs, approximately one third exhibits a novel mechanism of action. Innovative programs target a wide range of molecules implicated in immune signaling, such as cytokines and B and T cell antigens. Several promising first-in-class therapies can selectively modulate specific subsets of immune cells without compromising the entire immune system. In particular, biologics that target a subset of T cells, which are strongly implicated in autoimmune pathophysiology, could allow for specificity of immune suppression and thereby reduce adverse side effects. Based on clinical trials, IL-17-targeted therapies have demonstrated superiority over currently established therapies in achieving advanced clinical endpoints. Other agents which activate regulatory arms of the immune system have also shown promising clinical profiles. In addition, innovative programs that target molecules have only recently gained recognition of their therapeutic value in the treatment of psoriasis, including novel angiogenic proteins, signaling transduction proteins and novel nuclear receptors. Despite their recent implication in disease pathophysiology, many of these agents have also demonstrated clinical utility in the treatment of psoriasis and are likely to contribute to a diversified therapeutic landscape.

Scope

* A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of pharmacotherapy
* The changing molecular target landscape between market and pipeline and particular focal points of innovation
* Overview of how innovative products are contributing to the pipeline and market for psoriasis

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation
- Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
- Psoriasis - Pipeline Review, H1 2014
- Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2014
- Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2013